The Show and After Show Previews the 2025 ESMO Annual Congress

Prepare for a pivotal shift in the molecular oncology landscape at the 2025 European Society of Medical Oncology (ESMO) Annual Congress, to be held October 17 through 21, in Berlin, Germany.

The Show and After Show, co-hosts Kristie L. Kahl and Andrew Svonavec set the stage for the congress, highlighting key areas of anticipated interest for medical oncologists and oncology practice providers.

This year, the scientific program is heavily weighted towards leveraging technology to achieve unprecedented precision in oncology. Expect in-depth coverage of high-impact proffered paper sessions and special symposiums that will dissect the emerging role of artificial intelligence (AI). The focus will not just be on theoretical applications, but on tangible, data-driven outcomes: how AI can be deployed today to identify novel drug targets, accurately predict a patient's response to systemic treatments, and optimize patient stratification for ongoing and future clinical trials. The ability of these AI models to rapidly sift through "vast amounts of data at unprecedented speeds" is set to "accelerate breakthroughs across the board" in research and drug development.

To navigate this explosion of information, CancerNetwork® is excited to introduce SCOUT (Scientific Clinical Outcomes and Updates Today), a revolutionary "multi-agent intelligent assistant". Developed specifically for the oncology professional, SCOUT is "not a search tool" but a streamlined intelligence platform designed to deliver precise answers immediately, cutting through the noise and waste of traditional information retrieval. This new tool, accessible on every page of our website, represents "the future of clinical intelligence" and is essential for medical oncologists who must integrate complex data into actionable treatment plans.

The ESMO Annual Congress is set to offer practice-changing data with CancerNetwork's expert analysis to follow on how these innovations translate into "more hope and innovative solutions for patients worldwide". Oncologists can prepare to challenge their current paradigms and set the standard for evidence-based precision oncology.